Sandoz is continuing to show its appetite for sterile injectables and hospital drugs in the US by acquiring the rights to two mature generic injectables in the market for an undisclosed fee.
From Swiss player BE Pharmaceuticals, Sandoz will acquire the rights to generics of Merck’s Cubicin (daptomycin) 500mg and Emend (fosaprepitant...